Alkermes (ALKS) Q1 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Alkermes delivered a mixed first quarter for 2025, posting an earnings miss alongside a modest revenue beat as the expiration of a key royalty agreement continued to weigh heavily on the bottom line. The company reported revenue of $306.51 million, e… Read more Alkermes delivered a mixed first quarter for 2025, posting an earnings miss alongside a modest revenue beat as the expiration of a key royalty agreement continued to weigh heavily on the bottom line. The company reported revenue of $306.51 million, edging past the $304.11 million consensus by 0.79%, though that figure still represented a 12.5% decline year-over-year as the loss of royalties on INVEGA SUSTENNA slashed manufacturing and royalty revenues nearly in half. Earnings per share of $0.13 fell well short of the $0.24 consensus estimate, a miss of 46.90%, with GAAP net income sliding to $22.46 million from $38.95 million a year ago. Bright spots included LYBALVI, which delivered 23% revenue growth and 22% prescription growth, helping lift proprietary product net sales to $244.49 million. Management reaffirmed full-year guidance of $1.34 billion to $1.43 billion in total revenues and GAAP net income of $175 million to $205 million, while investors watch closely for topline results from the ALKS 2680 narcolepsy study expected early in the third quarter.